Premium
Immune‐mediated inner ear disease and parvovirus b19
Author(s) -
Cotter Cheryl S.,
Singleton George T.,
Corman Lourdes C.
Publication year - 1994
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-199410000-00009
Subject(s) - medicine , immunology , parvovirus , erythema infectiosum , immune system , antibody , antibody titer , titer , parvoviridae , virus
Human parvovirus B19 (HP‐B19), the etiologic agent of the common childhood illness erythema infectiosum, has been implicated in systemic immune disorders. Patients presenting with sensorineural hearing loss and/or dizziness, not readily categorized, were evaluated for immune‐mediated inner ear disease. Appropriate serologic studies including parvovirus B19 antibody titers were conducted. Thirty patients with suspected immune‐mediated inner ear disease were treated with corticosteroid trial for 5 to 7 days, then reexamined with repeat audiogram and/or vestibular testing. Seventeen patients with clinical response were treated with long‐term corticosteroids and cyclophosphamide. Six patients had positive HP‐B19 immunoglobulin M (IgM) titers and 8 patients had positive parvovirus immunoglobulin G (IgG) titers. All 14 patients responded to therapy. Parvovirus B19, therefore, is a possible etiology of immune‐mediated inner ear disease.